摘要 |
The insulin sensitivity enhancers, such as troglitazone, have the ability to treat and/or prevent hyperuricemia. They may be used for treating diseases such as gout, urinary calculus, hyperuricemic nephropathy and Lesch-Nyhan syndrome. Preferred insulin sensitivity enhancers are: i)5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione, ii)5-[4-(6-acetoxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione, iii)5-[4-(6-ethoxycarbonyloxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]-thiazolidine-2,4-dione, iv) 5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}thiazolidine-2,4-dione, v) 5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione, vi) 5-{4-[2-(N-methyl-N-pyrid-2-ylamino)ethoxy]benzyl}thiazolidine-2,4-dione, vii)5-(4-{2-[1-(4-pyrid-2'-ylphenyl)ethylideneaminooxy]ethoxy}benzyl) thiazolidine-2,4-dione, viii) 4-{4-[2-(2-phenyl-5-methyl-4-oxazolyl)ethoxy]benzyl}-3,5-isoxazolidinedione, ix) 5-{4-(5-methoxy-3-methylimidazo[4,5-b]pyridin-2-ylmethoxy)benzyl} thiazolidine-2,4-dione, x) 5-[4-(1-methylindolin-2-ylmethoxy)benzyl]thiazolidine-2,4-dione, xi) 5-[4-(1-methylbenzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione, xii) 5-[4-(6-methoxy-1-methylbenzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione, xiii) 5-[4-(5-hydroxy-1,4,6,7-tetramethylbenzimidazol-2-ylmethoxy)benzyl]-thiazolidine-2,4-dione, xiv) 5-{4-[3-(5-methyl-2-phenyloxazol-4-yl)propionyl]benzyl}thiazolidine-2,4-dione, or xv) 5-[6-(2-fluorobenzyloxy)-2-naphthylmethyl]thiazolidine-2,4-dione; or a pharmaceutically acceptable salt thereof.
|